Skip to content

NeuBase Therapeutics, Inc.: 10-K filed 2014-12-22

What NeuBase Therapeutics, Inc. reported in its annual report filed 2014-12-22 (fiscal FY 2014): 28 published measures, 92 facts as tagged in accession 0001387131-14-004117.

This filing

Form
10-K (annual report)
Filed
2014-12-22
Fiscal period
fiscal FY 2014
Accession
0001387131-14-004117 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NeuBase Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-09-3032,025,144USD
At 2013-09-305,743,865USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-09-305,273,122USD
At 2013-09-30479,737USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-09-3026,752,022USD
At 2013-09-305,264,128USD
At 2012-09-302,426,225USD
At 2011-09-30-4,781,753USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-07-01 to 2014-09-30-3,088,399USD92
2013-10-01 to 2014-09-30-9,130,664USD365
2014-04-01 to 2014-06-30-2,052,089USD91
2014-01-01 to 2014-03-31-1,968,251USD90
2013-10-01 to 2013-12-31-2,021,925USD92
2013-07-01 to 2013-09-30-1,803,447USD92
2012-10-01 to 2013-09-30-5,652,488USD365
2013-04-01 to 2013-06-30-1,338,431USD91
2013-01-01 to 2013-03-31-292,258USD90
2012-10-01 to 2012-12-31-2,218,352USD92
2011-10-01 to 2012-09-30-1,454,884USD366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-10-01 to 2014-09-30-5,360,132USD365
2012-10-01 to 2013-09-30-2,689,687USD365
2011-10-01 to 2012-09-30-1,753,829USD366

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-10-01 to 2014-09-3016,972,600USD365
2012-10-01 to 2013-09-305,180,169USD365
2011-10-01 to 2012-09-303,949,859USD366

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-10-01 to 2014-09-30-3,514,869USD365
2011-10-01 to 2012-09-30-33,403USD366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-09-30-43,313,548USD
At 2013-09-30-34,182,884USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-09-30104,425USD
At 2013-09-3029,755USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-10-01 to 2014-09-302,074,487USD365
2012-10-01 to 2013-09-30746,262USD365
2011-10-01 to 2012-09-30406,267USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-07-01 to 2014-09-30-3,076,632USD92
2013-10-01 to 2014-09-30-9,122,924USD365
2014-04-01 to 2014-06-30-2,056,416USD91
2014-01-01 to 2014-03-31-1,968,383USD90
2013-10-01 to 2013-12-31-2,021,493USD92
2013-07-01 to 2013-09-30-1,802,447USD92
2012-10-01 to 2013-09-30-4,620,916USD365
2013-04-01 to 2013-06-30-1,335,575USD91
2013-01-01 to 2013-03-31-668,143USD90
2012-10-01 to 2012-12-31-814,751USD92
2011-10-01 to 2012-09-30-3,286,408USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-09-3013,354,021USD
At 2013-09-305,168,245USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-10-01 to 2014-09-305,576USD365
2012-10-01 to 2013-09-304,689USD365
2011-10-01 to 2012-09-301,817USD366

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-09-305,273,122USD
At 2013-09-30479,737USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2014-09-30740,912USD
At 2014-05-30740,912USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2014-09-3017,810,400USD
At 2013-09-30545,865USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-10-01 to 2014-09-309,122,924USD365
2012-10-01 to 2013-09-304,620,916USD365
2011-10-01 to 2012-09-303,286,408USD366

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-10-01 to 2014-09-303,990,875USD365
2012-10-01 to 2013-09-302,610,120USD365
2011-10-01 to 2012-09-301,625,695USD366
2012-09-11 to 2012-09-1299,000USD2
2012-03-17 to 2012-03-18109,200USD2
2012-02-14 to 2012-02-15100,000USD2

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-09-3025,254,190shares
At 2013-09-3019,741,541shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-09-3070,063,045USD
At 2013-09-3039,444,988USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2014-09-30150,940USD
At 2013-09-3058,241USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2014-09-3046,515USD
At 2013-09-3028,486USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2013-10-01 to 2014-09-30-9,130,664USD365
2012-10-01 to 2013-09-30-5,652,488USD365
2011-10-01 to 2012-09-30-1,454,884USD366

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-10-01 to 2014-09-30555,735USD365
2012-10-01 to 2013-09-30312,541USD365
2011-10-01 to 2012-09-30135,552USD366
2012-09-18 to 2012-09-191,122USD2

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2013-10-01 to 2014-09-3017,850USD365
2012-10-01 to 2013-09-3013,356USD365
2011-10-01 to 2012-09-309,456USD366

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2013-10-01 to 2014-09-30448,456USD365
2012-10-01 to 2013-09-3077,789USD365
2011-10-01 to 2012-09-3078,273USD366

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2013-10-01 to 2014-09-308,479USD365
2012-10-01 to 2013-09-3090,759USD365
2011-10-01 to 2012-09-30112USD366

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2013-10-01 to 2014-09-30-7,740USD365
2012-10-01 to 2013-09-30-1,031,572USD365
2011-10-01 to 2012-09-301,831,524USD366

Inspect the source

Entity
NeuBase Therapeutics, Inc. / CIK 0001173281
Captured
SEC response SHA-256
0e0882fa147fcb0a3e5f3af54573abe947d9ade4d42095debd16c2d62da36e79

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001173281.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))